Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.76 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.62 |
| ▸ | DRD3 | P35462 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimeperidine SCHEMBL1649689 | 1.00 | OPRM1 (0.76) | OPRM1OPRD1MEN1KMT2ALMNA | |
| Trimeperidine SCHEMBL25235 | 1.00 | OPRM1 (0.76) | OPRM1OPRD1MEN1KMT2ALMNA | |
| Trimeperidine SCHEMBL9420815 | 0.99 | OPRM1 (0.78) | OPRM1OPRD1MEN1KMT2ALMNA | |
| Proheptazine SCHEMBL7618840 | 0.89 | LMNA (0.72) | OPRM1OPRD1MEN1KMT2ALMNA | |
| SCHEMBL3704187 | 0.82 | OPRM1 (0.54) | OPRM1OPRD1MEN1KMT2ALMNA | |
| SCHEMBL3707956 | 0.82 | ALDH1A1 (0.57) | OPRM1OPRD1MEN1KMT2ALMNA | |
| Betaprodine SCHEMBL186644 | 0.81 | LMNA (0.97) | OPRM1OPRD1MEN1KMT2ALMNA | |
| Betaprodine SCHEMBL248367 | 0.81 | LMNA (0.97) | OPRM1OPRD1MEN1KMT2ALMNA | |
| Betaprodine SCHEMBL25053 | 0.81 | LMNA (0.97) | OPRM1OPRD1MEN1KMT2ALMNA | |
| Alphaprodine SCHEMBL25054 | 0.81 | LMNA (0.97) | OPRM1OPRD1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6276 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20250319074-A1 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | UNIV EAST CAROLINA (US) | 2025-10-16 | — | — | US | claimed |
| US-12440489-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-10-14 | — | — | US | claimed |
| US-12383743-B2 | Treatment of addiction and dependency | TACA JR ARTURO C (US) | 2025-08-12 | — | — | US | claimed |
| EP-4581017-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2025-07-09 | — | — | EP | claimed |
| WO-2024254056-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | CATALENT ONTARIO LIMITED (CA) | 2024-12-12 | — | — | WO | claimed |
| US-12133922-B2 | Abuse resistant capsule | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2024-11-05 | — | — | US | claimed |
| US-20240343784-A1 | TREATMENT OF MEDICATION OVERUSE HEADACHE USING ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES | H LUNDBECK AS (DK) | 2024-10-17 | — | — | US | claimed |
| US-12036192-B2 | Combination treatments for opioid crisis | PRESTI MICHAEL (US) | 2024-07-16 | — | — | US | claimed |
| US-20240165111-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-05-23 | — | — | US | claimed |
| US-5958452-A | SUSTAINED RELEASE FORMULATION COMPRISING EXTRUDED BLEND OF DRUG, HYDROPHOBIC MATERIAL, HYDROPHOBIC FUSIBLE CARRIER DIVIDED INTO UNIT DOSE | EURO-CELTIQUE, S.A. (LU) | 1999-09-28 | — | — | US | claimed |
| WO-1999013799-A1 | SYNERGISTIC ANALGESIC COMBINATION OF OPIOID ANALGESIC AND CYCLOOXYGENASE-2 INHIBITOR | EURO-CELTIQUE, S.A. (LU) | 1999-03-25 | — | — | WO | claimed |
| EP-0785775-A4 | MELT-EXTRUDED ORALLY ADMINISTRABLE OPIOID FORMULATIONS | EURO CELTIQUE SA (LU) | 1998-08-19 | — | — | EP | claimed |
| EP-0785775-A1 | MELT-EXTRUDED ORALLY ADMINISTRABLE OPIOID FORMULATIONS | Euroceltique S.A. (LU) | 1997-07-30 | — | — | EP | claimed |
| EP-0731694-A4 | — | — | 1996-10-02 | — | — | EP | claimed |
| EP-0731694-A1 | OPIOID FORMULATIONS FOR TREATING PAIN | Euroceltique S.A. (LU) | 1996-09-18 | — | — | EP | claimed |
| CN-1130352-A | Method for relieving pain by orally administering 24-hour sustained-release opioid dosage form capable of rapidly increasing initial blood concentration of patient | EURO CELTIQUE SA (LU) | 1996-09-04 | — | — | CN | claimed |
| WO-1996014058-A1 | MELT-EXTRUDED ORALLY ADMINISTRABLE OPIOID FORMULATIONS | EURO-CELTIQUE, S.A. (LU) | 1996-05-17 | — | — | WO | claimed |
| WO-1995014460-A1 | OPIOID FORMULATIONS FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 1995-06-01 | — | — | WO | claimed |
| EP-0647448-A1 | Orally administrable opioid formulations having extended duration of effect | Euroceltique S.A. (LU) | 1995-04-12 | — | — | EP | claimed |